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Thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor subtype γ (PPARγ) activators that are clinically used
as an insulin sensitizer for glycemic control in patients with type 2 diabetes. Additionally, TZDs exhibit novel anti-inﬂammatory,
antioxidant, and antiproliferative properties, indicating therapeutic potential for a wide variety of diseases associated with diabetes
and other conditions. The clinical applications of TZDs are limited by the common major side eﬀect of ﬂuid retention. A better
understanding of the molecular mechanism of TZD-induced ﬂuid retention is essential for the development of novel therapies
with improved safety proﬁles. An important breakthrough in the ﬁeld is the ﬁnding that the renal collecting duct is a major site
for increased ﬂuid reabsorption in response to rosiglitazone or pioglitazone. New evidence also indicates that increased vascular
permeability in adipose tissues may contribute to edema formation and body weight gain. Future research should therefore be
directed at achieving a better understanding of the detailed mechanisms of TZD-induced increases in renal sodium transport and
in vascular permeability.
Copyright © 2008 T. Yang and S. Soodvilai. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Thiazolidinediones (TZDs), such as rosiglitazone and piogli-
tazone, are highly eﬀective for the treatment of type 2
diabetes and are widely prescribed. Unfortunately, ﬂuid
retention has emerged as the most common and serious side
eﬀect of TZDs and has become the most frequent cause of
discontinuation of therapy. The incidence of TZD-induced
ﬂuid retention ranges from 7% in monotherapy and to as
high as 15% when combined with insulin [1–3]. The ﬂuid
retention is often presented as peripheral edema, which
can progress into pulmonary edema and congestive heart
f a i l u r e .T Z Du s el e a d st oa6 - 7 %i n c r e a s ei nb l o o dv o l u m e
in healthy volunteers [4, 5]. This blood volume expansion
can dilute the red blood cell concentration, producing a
reduced hematocrit. In fact, changes in hematocrit have
been used as a surrogate marker for TZD-induced plasma
volume expansion. The ﬂuid retention is often resistant to
loop diuretics but is reversed by withdrawing the drug. Many
aspects of TZD-induced ﬂuid retention have been covered by
excellent review articles [6–12]. This review will emphasize
renal sodium retention and vascular hyperpermeability as
prominent mechanisms of TZD-induced ﬂuid retention. We
will also introduce several possible treatment strategies.
2. RENAL MECHANISM
The kidney is the key regulator of electrolyte balance and
water conservation. Fluid retention at the renal level is
suggested by evidence that TZD-induced edema is associated
with reduced urinary sodium and water excretion. Song
et al. reported that chronic three-day administration of
rosiglitazone to Sprague Dawley rats signiﬁcantly reduced
urine volume (by22%) and sodium excretion (by 44%) [13].
These ﬁndings lead us to speculate that renal mechanisms
play a major role in TZD-induced ﬂuid retention. TZDs may
cause renal ﬂuid reabsorption directly by aﬀecting tubular
transport, renal sodium retention, and vascular hyperper-
meability or indirectly by aﬀecting renal hemodynamics or
processes. Yang et al. examined the eﬀect of a PPARγ agonist,
GI262570 (farglitazar), on the glomerular ﬁltration rate,
eﬀective renal plasma ﬂow, and renal ﬁltration fraction in
chronically catheter-implanted conscious rats [14]. In this2 PPAR Research
study,glomerularﬁltrationratewasdeterminedbyusingﬂu-
orescein isothiocyanate (FITC)-inulin and renal blood ﬂow
by using para-aminohippurate (PAH). A 10-day infusion
of GI262570 decreased hematocrit, hemoglobin, and serum
albumin (all P<. 05), indicating volume expansion, but
did not alter glomerular ﬁltration rate, eﬀective renal plasma
ﬂow, or renal ﬁltration fraction. This indicates that PPARγ
agonist-induced volume expansion is not related to changes
in renal hemodynamics [14]. This observation is reinforced
by a human study in which the six-week administration of
pioglitazone to healthy volunteers led to sodium retention
without a signiﬁcant eﬀect on glomerular ﬁltration rate
or renal blood ﬂow [15]. This lack of change in renal
hemodynamics is, however, not universally reported. The
three-day administration of rosiglitazone in Sprague Dawley
rates induced a 35% reduction in creatinine clearance, an
indirect measure of the glomerular ﬁltration rate [13].
It is unclear whether or not this discrepancy is related
to diﬀerences in glomerular ﬁltration rate measurement
techniques or other experimental protocols.
The lack of solid evidence to support the alteration of
renal hemodynamic parameters following treatment with
PPARγ ligands suggests the possibility of a direct inﬂuence
on tubular transport processes. The regulation of NaCl
reabsorption in the kidney can occur at the level of
sodium transport proteins lining the renal epithelia. These
sodium transporters include basolateral Na-K-ATPase, and
the following apical transporters that vary with individual
nephron segments: the sodium hydrogenexchanger subtype
III (NHE3) and the sodium phosphate cotransporter sub-
type II (NaPi-2) in the proximal convoluted tubule, the
bumetanide-sensitive Na-K-2Cl cotransporter (NKCC2 or
BSC1) in the thick ascending limb, the thiazide-sensitive Na-
Cl cotransporter (NCC or TSC) in the distal convoluted
tubule, and the amiloride-sensitive sodium channel (ENaC)
in the collecting duct. The major water channel proteins
(aquaporins, AQPs) in the kidney include AQP1-4, of which
AQP1 and AQP2 function on the apical membrane, and
AQP3 and AQP4 on the basolateral membrane [16]. The
study of Song et al. is the ﬁrst to provide a comprehensive
examinationoftheeﬀectsofPPARγ agonistsonvariousrenal
sodium and water transport proteins [13]. In that study, a
three-day rosiglitazone treatment increasedthe whole kidney
protein level of the α-1 subunit of Na-K-ATPase, NKCC2,
NHE3, AQP2, and AQP3 [13]. These ﬁndings suggest that
increases in sodium transport may occur in the proximal
convoluted tubule and the thick ascending limb.
The collecting duct reabsorbs approximately 2-3% of
the ﬁltered sodium load primarily through ENaC, which is
comprised of three subunits, α, β,a n dγ. These proteins are
vital to day-to-day adjustment of sodium reabsorption and
are regulated by the hormones aldosterone and insulin [17–
19]. A key mediator of aldosterone activation of ENaC is
serumandglucocorticoidregulatedkinase1(SGK1)[20,21].
Activated SGK1 prevents ENaC degradation by inactivating
theubiquitinligaseNedd4-2[22].Nedd4-2interactswiththe
PY motif of ENaC leading to endocytosis and degradation
of the channel [22]. Prior to the conditional knockout
(KO) studies, three major lines of evidence indicated that
the activation of sodium transport processes in the distal
nephron may underlie TZD-induced ﬂuid retention. First,
within the kidney, PPARγ is highly expressed in the renal
medullary collecting duct, with lower expression levels in
glomeruli, proximal tubules, and microvasculature. This was
demonstrated by both RT-PCR and microdissection as well
as by in situ hybridization techniques [23–25]. Second,
in a cultured human cortical collecting duct (CCD) cell
line, PPARγ agonists increased levels of cell surface α-
ENaC. This is paralleled by an increase in SGK1 mRNA,
which is abolished by pretreatment with a speciﬁc PPARγ
antagonist, leading to increased levels of cell surface α-
ENaC. Electrophoretic mobility shift assays further suggest
that these eﬀects are caused by the binding of PPARγ to
a speciﬁc response element in the SGK1 promoter [20].
Third, in vivo evidence shows that GI262570 stimulates
sodium and water reabsorption from the distal nephron
in Sprague Dawley rats [26]. This evidence comes from
increasesinplasmasodiumandchlorideconcentrationswith
concomitant decreases in plasma potassium concentration.
Reciprocal changes in plasma NaCl and potassium levels are
typically seen as a consequence of renal mineralocorticoid
activation promoting NaCl reabsorption and potassium
secretion in the distal nephron [26]. Additionally, mRNA
levels for a group of genes involved in distal nephron sodium
andwaterabsorptioninthekidneymedullaarechangedwith
GI262570 treatment [26].
The involvement of the distal nephron in TZD-induced
ﬂuid retention has been assessed in two independent studies
using mice with a collecting duct-speciﬁc deletion of PPARγ
(CD PPARγ KO) [27, 28]. In both studies, the expression of
Cre recombinase was driven by an AQP2 promoter highly
speciﬁc to the collecting duct. In these two studies, the
experimental approaches for assessment of ﬂuid retention
were quite diﬀerent: a combination of hematocrit, plasma
aldosterone levels, and Evans blue (EB) dye-based mea-
surement of plasma volume in one study (see Figure 1)
[28] and determination of total water content in the other
[27]. Remarkably, both studies reported a similar phenotype
in that the conditional PPARγ knockout mice proved to
be resistant to the rosiglitazone- or pioglitazone-induced
body weight gain and plasma volume expansion found in
mice expressing PPARγ in the collecting duct. As shown
in Figure 1, a nine-day rosiglitazone treatment induced a
gradual and signiﬁcant increase in body weight in ﬂoxed
mice when compared to untreated ﬂoxed controls (2.74 ±
0.25 versus 1.05 ± 0.16 gram, on day 9, P<. 05). In
contrast, body weight gains between rosiglitazone-treated
and untreated CD PPARγ KO mice were not signiﬁcantly
diﬀerent (0.90 ± 0.25 versus 0.81 ± 0.19 gram, on day
9, P>. 05). Rosiglitazone treatment in the control mice
induced plasma volume expansion, which was reﬂected by
a signiﬁcantly decreased hematocrit and plasma aldosterone
levels as well as by a 32.2% increase in plasma volume as
assessed by the EB dye technique. In contrast, rosiglitazone-
treated CD PPARγ KO mice exhibited nonsigniﬁcant trends
toward change in these parameters (see Figure 2). These two
studies also provided evidence that exposure of primary
collecting duct cells to PPARγ ligands leads to increasedT. Yang and S. Soodvilai 3
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Figure 1: Body weight gains in untreated and rosiglitazone (RGZ)-
treated PPARγf/f mice (a) and CD PPARγ knockout mice (b)
(adapted from [28]). ∗, P<. 05 versus vehicle at the corresponding
time point.
sodium transport as assessed by measurements of 22Na+ ﬂux
and transepithelial resistance.
Guan et al. examined the eﬀects of pioglitazone on the
expression of α-, ß-, and γ-ENaC subunits in cultured inner
medullarycollectingduct(IMCD)cells[27].Notably,within
one hour following treatment of IMCDs with pioglitazone
(1μM), γ-ENaC mRNA expression increased roughly 10
folds before gradually diminishing. This stimulatory eﬀect
appeared to be speciﬁc for γ-ENaC mRNA, because α-ENaC
and ß-ENaC mRNA levels did not show any change in
response to treatment with pioglitazone. Interestingly, PPAR
response elements (PPREs) are identiﬁed in intron 1 but not
in the 5  ﬂanking region of the γ-ENaC gene. Chromatin
immunoprecipitation (ChIP) of genomic DNAisolated from
cultured mouse IMCDs revealed a physical interaction
between PPARγ and γ-ENaC genomic DNA. Somewhat
unexpectedly, the PPARγ binding site was shown to be
located outside intron 1 of the γ-ENaC gene. Overall, these
data support γ- E N a Ca sad i r e c tt a r g e tg e n eo fP P A R γ in the
collecting duct cells, although the exact mechanism remains
to be elucidated.
However,theroleofENaCasadirecttargetofPPARγ has
not always been demonstrable. Nofziger et al. reported that,
in collecting duct cell lines, PPARγ agonists failed to enhance
basal or insulin-stimulated sodium transport as assessed by
measurement of short-circuit current (Isc) [29]. This study
also did not ﬁnd that PPARγ-induced changes in the amount
of SGK1 transcript or protein expression. Additionally, there
is no solid evidence for major changes in renal expression
of any of the ENaC subunits in response to PPARγ ligands
in vivo [13, 26, 30]. More recently, Vallon et al. reported
that collecting duct-speciﬁc gene inactivation of α-ENaC
in the mouse does not attenuate the rosiglitazone-induced
body weight gain [31]. In this study, the Hoxb-7 promoter
was used to inactivate α-ENaC in the collecting duct, while
leaving ENaC expression in the cortical connecting tubule
(CNT) intact [32]. As expected, in the ﬂoxed control mice,
rosiglitazone treatment (320mg/kg diet) rapidly increased
body weight (ΔBW day 11: 4.5 ± 0.8% versus 1.1 ± 0.6%,
P<. 05) and lowered hematocrit (44 ± 1.0% versus 47 ±
1%,P<. 0005),whilerosiglitazonetreatmentincreasedbody
weight (ΔBW: 7.3 ± 0.9% versus 0.9 ± 0.7%, P<. 0005) and
lowered hematocrit (42 ± 2% versus 47 ± 1%, P<. 05)
in α-ENaC collecting duct knockout mice. These data may
argue against collecting duct ENaC playing a signiﬁcant role
in mediating the adverse eﬀect of rosiglitazone. However,
involvement of ENaC activity in the CNT cannot be ruled
out. To resolve this issue, AQP2-Cre mice could be used to
inactivate ENaC in the entire collecting duct system.
The negative results discussed above prompt consid-
eration of alternative mechanisms for explaining PPARγ-
mediated increases in distal tubular ﬂuid reabsorption.
There is a signiﬁcant amiloride-insensitive component in the
rosiglitazone-induced increases in sodium transport [28].
The possibility exists that increased reabsorption may occur
by way of a paracellular route. For example, PPARγ may
regulate the tight junction leading to altered permeability
to sodium or other electrolytes. In an in vitromodel of dif-
ferentiating normal human urothelial (NHU) cells, PPARγ
activation in conjunction with epidermal growth factor
receptor (EGFR) blockade led to the de novo expression of
claudin 3 mRNA and protein and downregulation of claudin
2 transcription [33]. These results suggest a role for PPARγ
andEGFRsignalingpathwaysinregulatingthetightjunction
formation in NHU cells. There is an intriguing possibility
thatasimilarmechanismmayoperateinrenalepithelialcells.
Another possible mechanism is that PPARγ may regulate
transport of ions other than sodium. Further studies are
clearly needed to explore not only ENaC-dependent, but also
ENaC-independent mechanisms, for TZD-activated ﬂuid
reabsorption in the distal nephron.
3. VASCULAR MECHANISM
PPARγ is expressed in the vascular system [34], includ-
ing endothelial cells [35, 36], vascular smooth muscle
cells (VSMC) [37]a sw e l la sm o n o c y t e / m a c r o p h a g e s[ 38,
39]. Several lines of evidence suggest that PPARγ regu-
lates various aspects of vascular function, including capil-
lary permeability. Increased capillary permeability leads to4 PPAR Research
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Figure 2: Changes in plasma volume in PPARγf/f and CD PPARγ
knockout mice following rosiglitazone (RGZ) treatment (adapted
from [28]). (a) Hematocrit (Hct) in PPARγf/f and CD PPARγ
knockout mice before and after RGZ treatment. (b) Plasma
aldosterone levels in PPARγf/f and CD PPARγ knockout mice
following RGZ treatment. (c) Determination of plasma volume in
PPARγf/f and CD PPARγ KO mice by the Evans blue (EB) dye
technique.
extravasation of ﬂuid and is thought to contribute to edema
in patients treated with TZDs. Donnelly et al. were the ﬁrst
to examine the direct eﬀect of rosiglitazone on endothelial
barrier function using an in vitro system of pulmonary
arteryendothelialcellmonolayers.Transendothelialalbumin
ﬂux was measured using EB dye-labeled albumin. They
found that exposure to high concentrations of rosiglitazone
for four hours increased transendothelial albumin ﬂux
dose-dependently, with a noticeable eﬀect at 10μMa n da
maximal eﬀect at 100μM. This hyperpermeability response
to high concentrations ofrosiglitazone wasfullyreversible by
washingrosiglitazoneoﬀthemonolayer.Afterincubationfor
24 to 48 hours, the eﬀect of rosiglitazone began to subside.
High concentrations of rosiglitazone (0.1–1mM) are also
needed to induce a vasodilator eﬀect in isolated arteries [40].
Future studies, ideally employing gene knockout mice, may
determine the extent of PPARγ mediation of the vascular
response to high concentrations of TZDs. The mechanism of
TZD-inducedcapillarypermeabilityisnotwellcharacterized
but may involve a number of factors, notably vascular
endothelial growth factor (VEGF), nitric oxide, and protein
kinase C, each of which is discussed below.
VEGF is a potent cytokine that augments vascular per-
meability in tumors, healing wounds, retinopathies, many
important inﬂammatory conditions, and certain physiologi-
calprocesses,suchasovulationandcorpusluteumformation
[41]. VEGF is estimated to be 50 times more potent than
histamine in enhancing vascular permeability [41]. The gene
transfer of naked plasmid DNA encoding the 165-amino
acid isoform of VEGF in patents with peripheral artery
disease causes peripheral edema [42]. Evidence suggests an
involvement of VEGF in TZD-induced edema. The study
of Emorto et al. was the ﬁrst to report that plasma levels
of VEGF are signiﬁcantly increased in troglitazone-treated
subjects (120.1 ± 135.0pg/mL) compared with those treated
with diet alone (29.2 ± 36.1pg/mL), sulfonylurea (25.8 ±
22.2pg/mL), or insulin (24.6 ± 19.0pg/mL). The eﬀect of
troglitazone on increased VEGF levels was further supported
by plasma VEGF levels in ﬁve patients before treatment (20.2
± 7.0pg/mL), after three months of troglitazone treatment
(83.6 ± 65.9pg/mL), and three months after discontinuation
(28.0 ± 11.6pg/mL). These authors further demonstrated
that troglitazone, as well as rosiglitazone, at the plasma
concentrations observed in patients, increased VEGF mRNA
levels in 3T3-L1 adipocytes. The ﬁnding suggests that
PPARγ activation may directly stimulate expression of VEGF
that leads to tissue edema. However, it is puzzling that
several other studies show that PPARγ negatively regulates
VEGF signaling. In transformed and primary endometrial
cells rosiglitazone or 15-deoxy-delta 12,14-prostaglandin
J2 (15d-PGJ2) decreased VEGF protein secretion [43]. In
transiently transfected Ishikawa cells, rosiglitazone repressed
VEGF gene promoter-luciferase activation with an IC [37]
approximately 50nM. By using truncated and mutated
VEGF promoter constructs, this study further revealed that
the PPARγ-regulated domain is a direct repeat (DR)-1 motif
−443bp upstream of the transcriptional start site [43].
Similarly, rosiglitazone attenuated VEGF-induced prolifera-
tion and migration of human pulmonary valve endothelial
cells (HPVECs) [44]. Rosiglitazone also antagonized VEGF-
induced nuclear factor translocation in activated T cells sub-
type c1 (NFATc1) [44]. Furthermore, rosiglitazone markedly
decreased VEGF-induced tube formation and cell migration
in human umbilical vein endothelial cells [45]. Taking these
studies together, it seems likely that PPARγ exerts a dual
eﬀect on VEGF signaling, possibly depending on cell type.
Nitric oxide (NO) is a ubiquitous, naturally occurring
molecule found in a variety of cell types and organ systems.
Endothelial cells are rich in NO, which has been shownT. Yang and S. Soodvilai 5
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Figure 3: The mechanism for thiazolidinedione- (TZD-) induced
edema. In the renal collecting duct, PPARγ activation increases
sodium reabsorption through ENaC-dependent and independent
mechanisms. In the blood vessels of adipose tissues, PPARγ ligands
activate PKCß, VEGF, and NO, which together lead to increased
endothelial permeability. The increased renal sodium retention
at the level of the collecting duct in conjunction with increased
vascular permeability may determine edema development.
to regulate many aspects of vascular function, including
vascular permeability. Polikandriotis et al. report that 15d-
PGJ2 and ciglitazone increase cultured endothelial cell NO
releasewithoutincreasingtheexpressionofendothelialnitric
oxide synthase (eNOS) [46]. This study provided further
evidence that PPARγ activation leads to eNOS ser1177
phosphorylation [46]. It seems plausible that the stimulation
of eNOS-derived NO may contribute to TZD-induced
edema. St-Pierre et al. examined the eﬀect of rosiglitazone
on muscle vasopermeability and NO system in the fructose-
fed rat model [47]. In this study, extravasation of EB dye in
vivo in speciﬁc muscle groups was used to assess vascular
permeability.Fructose-fedratstreatedwithrosiglitazonehad
a 30–50% increase in extravasation of EB in the the Rectus
femoris, soleus, gastrocnemius lateralis, vastus lateralis, and
tibialis cranialis skeletal muscles [47]. In homogenates of
skeletal muscles (vastus lateralis) from fructose-fed rats,
rosiglitazone resulted in a signiﬁcant increase in nitric oxide
synthase (NOS) activity and eNOS immunoreactive content
compared to the control animals [47]. Unexpectedly, the
immunoreactive level of the most abundant muscle NOS
isoforms, neuronal NOS (nNOS), remained unchanged.
Protein kinase C (PKC) plays a major role in deter-
mining vascular permeability through phosphorylation of
the cytoskeleton proteins that form the tight intercellular
junction [48–51]. In the study of Sotiropoulos et al., rosigli-
tazone treatment selectively activated PKC in fat and retinal
tissues in parallel with the increased vascular permeability
in these tissues [52]. The activation of PKC is evaluated by
determining the enzyme activity together with tissue levels
of diacylglycerol (DAG), a strong PKC activator [52]. These
investigators tested the eﬀect of PKCβ inhibition and gene
knockout but did not determine speciﬁc PKC isoforms. They
found that posttreatment with ruboxistaurin (RBX), a PKCβ
inhibitor, eﬀectively attenuated the increases in capillary
permeability, water content, and weight of epididymal fat,
as well as the increase in body weight associated with
rosiglitazone treatment; this ﬁnding was also conﬁrmed by
using PKCβ KO mice [52].
4. POTENTIAL THERAPIES
4.1. Inhibitionofsodiumtransportin
thecollectingduct
The use of diuretics for management of TZD-induced ﬂuid
retention has been evaluated by several case reports [2,
53] and, recently, by a controlled trial [54]. Most case
reports show that the edema is refractory to a loop diuretic
(furosemide) and that the symptoms resolve only after
discontinuation of TZD. The recent controlled trial involved
381 patients with type 2 diabetes. It examined the eﬀect
of three diuretics that act with diﬀerent mechanisms on
rosiglitazone-induced body weight gain and plasma volume
[54]. The diuretics included furosemide, which inhibits the
Na-K-Cl cotransporter in the thick ascending limb of the
loop of Henle, hydrochlorothiazide (HCTZ), which acts to
inhibit the Na-Cl cotransporter in the distal convoluted
tubule, and spironolactone (SPIRO), which is an ENaC
inhibitor in the collecting duct. The degree of ﬂuid retention
in this study was evaluated by measuring changes in the
hematocrit as an index of changes in plasma volume, body
weight, total body water, and extracellular ﬂuid changes
determined by noninvasive bioelectrical impedance with an
Akern soft tissue analyzer. SPIRO and HCTZ both eﬀectively
reduced ﬂuid retention and body weight while furosemide
had only a limited eﬀect. The eﬀectiveness of SPIRO may
be attributable to the ability of this diuretic to interfere
with the sodium retaining action of PPARγ in the collecting
duct. It is unclear whether the same mechanism can explain
the action of HCTZ. Thiazide diuretics act primarily in
the proximal part of the distal convoluted tubules where
they inhibit Na+/Cl
− cotransport [55, 56], but they are
also reported to inhibit salt and water reabsorption in the
medullary collecting duct [57]. The reason for the lack of
diuretic response of TZD-treated diabetics to furosemide is
not entirely clear, but one possible explanation might be the
lack of distal eﬀect of this loop diuretic. Another possibility
is that TZD-induced ﬂuid retention may be associated with
impaired transport machinery in the thick ascending limb.
Possibly secondary to the volume expansion, the plasma
level of atrial natriuretic factor (ANF) is elevated in TZD-
treated diabetics [54]. ANF inhibits NaCl reabsorption in
the loop of Henle as well as in other sites of nephron
through the activation of guanylyl cyclase receptors that
release cyclic GMP [58]. It also remains possible that PPARγ
may negatively aﬀect NaCl transport in the loop of Henle.
The experimental evidence favoring ENaC as a potential
target of PPARγ in the distal nephron seems to provide a
rationale for theuseof amiloride as aspeciﬁcENaCinhibitor
for treatment of TZD-induced ﬂuid retention. Unfortu-
nately, amiloride was not included in this clinical trial
[54]. In the mouse, pretreatment with amiloride eﬀectively
prevents body weight gain and ﬂuid retention produced6 PPAR Research
by pioglitazone. However, in the rat model, posttreatment
with amiloride unexpectedly exacerbates the ﬂuid retention
induced by farglitazar. It is unclear whether this discrepancy
between the studies is due to species diﬀerences, PPARγ
ligandactivity,orthediﬀerenttimingofamiloridetreatment.
4.2. CombinationofaPPARγ andaPPARαagonist
Boden et al. examined the eﬀect of the combined use
of rosiglitazone and fenoﬁbrate in patients with type 2
diabetes [59]. Compared with rosiglitazone alone, rosigli-
tazone/fenoﬁbrate proved signiﬁcantly more eﬀective in
lowering fasting free fatty acid levels and tended to be more
eﬀective in achieving plasma glucose control. Interestingly,
rosiglitazone/fenoﬁbrate completely prevented the increase
in body weight and body water content associated with
rosiglitazone. This study is the ﬁrst to show that the
combined use of a PPARγ and a PPARα agonist can prevent
rosiglitazone-induced ﬂuid retention. The investigators did
not propose a mechanism to explain this phenomenon.
The two PPAR isoforms occur in diﬀerent locations along
the nephron. PPARα mRNA is found predominately in the
cortexandisspeciﬁcallylocalizedintheproximalconvoluted
tubule(PCT).PPARγ isabundantintherenalinnermedulla,
speciﬁcally localized to the inner medullary collecting duct
[23, 25]. The diﬀerence in nephron localization does not
seem to favor the direct interaction between the two PPAR
isoforms. However, it remains possible that low PPARα
activity in the collecting duct may antagonize the sodium-
retaining action of PPARγ. Future studies are needed to
investigate whether an interaction occurs in the collecting
duct or another location.
Dual PPARα/γ agonists have been developed by several
pharmaceutical companies, and some have undergone or are
currently undergoing clinical trials [60–62]. Unfortunately,
muraglitazar, the ﬁrst dual PPARα/γ agonist, has been
associated with an excessive incidence of major adverse car-
diovascular events, including myocardial infarction, stroke
and transient ischemic attack, chronic heart failure and
death [62]. This ﬁnding raises signiﬁcant safety concerns
about the dual agonists as well as the combination of a
PPARγ and a PPARα agonist. In the study of Boden et al.,
rosiglitazone/fenoﬁbrate appeared to be well tolerated [59].
The safety issues may be related to the ratio of PPARγ to
PPARα. The ratios are ﬁxed for the dual agonists, but can
be varied by changing the proportion of PPARγ and PPARα
agonists. It should be pointed out that Boden’s study was
limited to a small number of patients and a short period
of treatment [59]. The safety issue regarding the combined
use of a PPARγ and PPARα a g o n i s tn e e d st ob ec a r e f u l l y
evaluatedinlarger-scaleandlonger-termclinicaltrialsaswell
as animal studies.
4.3. InhibitionofproteinkinaseC
There is functional evidence suggesting the involvement of
vascular permeability in TZD-induced body weight gain
and ﬂuid retention [52]. Therefore, targeting vascular per-
meability may provide a potential therapeutic strategy for
this side eﬀect of the TZDs. In an animal study, the use
of a PKCβ inhibitor, RBX, to target vascular permeability
eﬀectively attenuated the increases in TZD-induced body
weight gain [52]. Is there any safety issue related to RBX?
In the animal models tested, including Zucker and lean fatty
rats, and mice, RBX reduced rosiglitazone-induced capillary
permeability, but had no signiﬁcant eﬀect on the baseline
capillary permeability without rosiglitazone treatment. In
this short-term animal study, the compound appears to be
welltolerated.AnotherpositivenoteisthatRBXisbeingused
in clinical trials for diabetic microvascular complications. In
these trials, as well as in animal studies, RBX shows promise
for treatment of diabetic retinopathy and nephropathy
without noticeable side eﬀects [63, 64].
5. CONCLUSIONS
The ﬂuid retention and rapid body weight gain induced by
TZD treatment are caused by increased ﬂuid reabsorption in
the distal nephron as well as increased vascular permeability
in adipose tissues (see Figure 3). The molecular mechanisms
of the eﬀects of TZDs in renal collecting duct and in blood
vessels remain unknown. Despite documentation of ENaC as
a molecular target of TZDs in the collecting duct, increasing
evidence indicates ENaC-independent mechanisms that may
involve changes in paracellular transport. PKCß is shown
to mediate TZD-induced vascular permeability in adipose
tissues. More studies are required for determination of the
signaling pathway responsible for PPARγ-dependent tissue-
speciﬁc activation of PKCß. Currently, there are no eﬀective
therapiesforthesideeﬀectsofTZDsexceptdrugwithdrawal.
A number of potential treatment strategies that target
collecting duct sodium transport (amiloride) and vascular
permeability (PKC inhibitors) have been developed from
animal studies and should be evaluated by future clinical
trials.
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